Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

NCT05171049 is registered in ClinicalTrials.gov with Anthos Therapeutics, Inc. as lead sponsor.

NCT NCT05171049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05171049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE
Lead sponsor
Anthos Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
May 5, 2022
Completion date
February 4, 2026
Enrollment
1,150 (actual)
Sites
209

Conditions

As the registry lists them; a condition with its own page is linked.

deep venous thrombosis, pulmonary embolism, venous thromboembolism